,trastuzumab deruxtecan
astrazeneca,daiichi sankyo
['paradigm', 'breast', 'enhertu']
enhertu benefit in her2-low breast cancer wows at asco; signals shifting therapy, dx paradigms. oncologists at asco cheered data showing the drug significantly cut the risk of disease progression or death, but experts wondered how existing her2... 